Liberate bio integrates quantum-si's next-generation protein sequencing™ platform to enhance gene therapy development

Branford, conn.--(business wire)--quantum-si incorporated (nasdaq: qsi) (“quantum-si,” “qsi” or the “company”), the protein sequencing company™, today announced that liberate bio, a boston-based biotech unleashing the potential of genetic medicines with novel delivery vehicles, has integrated the platinum® next-generation protein sequencer™ (“ngps”) into their platform for developing novel gene therapies with improved targeting capabilities. liberate is using the sequencer's protein barcoding a.
QMCO Ratings Summary
QMCO Quant Ranking